Boardroom Alpha
Meeting calendar
PFSA · Special meeting · Friday, September 18, 2026

Profusa Inc

6 nominees · 2 ballot items.

Profusa stockholders will vote on a discretionary 1-for-2 to 1-for-12 reverse stock split amendment and authorization to adjourn the special meeting to solicit additional votes if needed.

Market cap
$300K
1Y TSR
-99.9%
Board grade
D
Record date
Aug 19, 2026
Filing
DEF 14A
Meeting concluded · Sep 18, 2026

Follow how the vote landed and what changed on Profusa Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.

Proposals

On the ballot2

  1. 1

    Reverse Stock Split Proposal

    ManagementBoard: FOR

    Approve an amendment to the Amended and Restated Certificate of Incorporation authorizing the Board, in its discretion, to effect one or more reverse stock splits of the Company’s common stock between 1-for-2 and 1-for-12, with aggregate splits not exceeding 1-for-12, at any time through September 18, 2028, without further stockholder approval.

    More detail

    The proposal asks stockholders to approve a Certificate of Incorporation amendment permitting the Board to carry out one or more reverse splits of the common stock through September 18, 2028. The cumulative reverse-split ratio could range from 1-for-2 to 1-for-12, with the Board selecting the precise ratio and timing without another stockholder vote. If implemented, shares would be combined proportionally, while the authorized share count and par value would remain unchanged. Management’s principal objective is to increase the trading price enough to regain and maintain compliance with Nasdaq’s $1.00 minimum bid-price requirement. The company has a significant Nasdaq compliance backdrop, including prior 1-for-75, 1-for-25, and 1-for-4 reverse splits in 2026 and an ongoing effort to satisfy bid-price and other listing requirements. Management also cites preserving Nasdaq access, maintaining financing alternatives such as S-3 shelf eligibility and an equity line of credit, improving liquidity, and attracting institutional investors. The Board argues that a ratio range is necessary because the appropriate ratio depends on the stock price, market conditions, expected price stability, liquidity, and market capitalization at the time of implementation. The Board retains authority to abandon the split if it later determines that implementation is not in the Company’s or stockholders’ best interests. Risks disclosed include post-split selling pressure, renewed delisting risk, lower liquidity, odd-lot consequences, reduced market capitalization, and potential greater dilution from future issuances because authorized shares are not reduced. The Board recommends FOR because it believes the flexibility and potential listing and financing benefits outweigh these risks.

  2. 2

    Adjournment Proposal

    ManagementBoard: FOR

    Authorize the Company to adjourn the special meeting one or more times, for up to 30 days, if necessary or appropriate to solicit additional proxies when there are insufficient votes to approve the Reverse Stock Split Proposal.

    More detail

    The proposal asks stockholders to authorize one or more adjournments of the special meeting if the Company lacks enough votes to approve the reverse stock split. Any adjournment would be used to solicit additional proxies rather than to introduce a new substantive matter. The filing states that the proposal would be presented only if a quorum exists and the reverse-split vote is insufficient at the meeting. An adjournment may last for no more than 30 days. The mechanism is intended to give management additional time to obtain support for the reverse split, which the Company views as important to Nasdaq compliance and financing access. Approval requires the affirmative vote of a majority of the voting power present in person or represented by proxy and entitled to vote on the proposal. Abstentions have the same effect as votes against, while broker non-votes have no effect. The Board recommends FOR because adjournment could help secure the votes needed for the reverse-split authorization. The proposal is procedural and does not itself implement a reverse split or amend the Company’s charter. Its practical significance is that it could delay final resolution of the principal proposal while management continues solicitation efforts.

Director elections

Nominees on the ballot6

Not independent
Tenure on this board
5.6 yrs
Also a director at
Traws Pharma Inc (TRAW)Transcode Therapeutics Inc (RNAZ)
Ownership

Top institutional holders10

Latest 13F quarter
1HRT FINANCIAL LP28.2%170,946$19
2StoneX Group Inc.2.8%16,879$6K
3GEODE CAPITAL MANAGEMENT, LLC2.7%16,417$2K
4VANGUARD CAPITAL MANAGEMENT LLC0.7%3,939$457
5Tower Research Capital LLC (TRC0.6%3,761$438
6IFP Advisors, Inc0.5%3,000$350
7MORGAN STANLEY0.3%1,600$186
8FMR LLC0.1%500$58
9SBI Securities Co., Ltd.0.1%404$47
10SkyView Investment Advisors, LLC0.0%265$0
Filings

Profusa Inc proxy statements and SEC reports

Annual & quarterly reports (10-K, 10-Q)
Proxy statements (DEF 14A)
Reference

Frequently asked questions

When is the Profusa Inc 2026 special meeting?
Profusa Inc (PFSA) holds its 2026 special shareholder meeting on Friday, September 18, 2026.
What is the record date for the Profusa Inc 2026 meeting?
The record date for the Profusa Inc 2026 meeting is Wednesday, August 19, 2026. Shareholders of record on or before that date are eligible to vote.
Who are the director nominees for Profusa Inc's 2026 meeting?
The board is presenting 6 director nominees at the Profusa Inc 2026 meeting, listed with their independence status and background.
What proposals will shareholders vote on at the Profusa Inc 2026 meeting?
Shareholders will vote on 2 proposals at the Profusa Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer